TY - JOUR
T1 - Safety and effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft percutaneous coronary interventions
T2 - Insights from the Veterans Affairs CART program
AU - Aggarwal, Vikas
AU - Stanislawski, Maggie A.
AU - Maddox, Thomas M.
AU - Nallamothu, Brahmajee K.
AU - Grunwald, Gary
AU - Adams, Jill C.
AU - Ho, P. Michael
AU - Rao, Sunil V.
AU - Casserly, Ivan P.
AU - Rumsfeld, John S.
AU - Brilakis, Emmanouil S.
AU - Tsai, Thomas T.
N1 - Funding Information:
The views expressed in this paper are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. Dr. Aggarwal is supported by American Heart Association post-doctoral fellowship award 13POST16340011 . Dr. Maddox is supported by VA Health Services Research and Development career development award HSR&D-CDA 08-021 . Dr. Brilakis is a consultant for and has received speaker honoraria from St. Jude Medical, Terumo, Janssen, Sanofi-Aventis, Asahi, Abbott Vascular, and Boston Scientific; has received research support from Guerbet ; and Dr. Brilakis’ spouse is an employee of Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2014 American College of Cardiology Foundation.
PY - 2014/10/28
Y1 - 2014/10/28
N2 - Background Stenosis of saphenous vein grafts (SVGs) after coronary artery bypass grafting (CABG) is common and often requires percutaneous coronary interventions (PCI) for treatment. However, data for the effectiveness of drug-eluting stents (DES) versus bare-metal stents (BMS) in SVG-PCI are unclear. Objectives This study sought to examine the association between DES versus BMS used during SVG PCI and clinical outcomes in the national Veterans Affairs integrated healthcare systemMethods We studied a national cohort of 2,471 post-CABG veterans undergoing SVG-PCI between 2008 and 2011 at all Veterans Affairs hospitals and compared clinical outcomes of between those receiving DES and BMS. Clinical outcomes included procedural complications, myocardial infarction (MI), and all-cause mortality. Comparisons were made in a propensity-matched cohort using Cox proportional hazards regression models-absp. Results DES were used in 1,549 SVG-PCI patients (63%) and the use of DES increased progressively with each calendar year (50% in 2008 to 69% in 2011). Incidence of procedural complications was low and comparable in both groups (2.8% among BMS vs. 2.3% among DES patients; p = 0.54). During long-term (>2 years) follow-up, use of DES was associated with lower mortality than BMS (hazard ratio [HR]: 0.72; 95% confidence interval [CI]: 0.57 to 0.89) and similar rates of MI (HR: 0.94; 95% CI: 0.71 to 1.24) in the propensity-matched cohort-absp. Conclusions In a national cohort of veterans, we observed widespread and increasing use of DES during SVG-PCI. In long-term follow-up, compared with BMS, DES use was safe and effective in SVG-PCI patients.
AB - Background Stenosis of saphenous vein grafts (SVGs) after coronary artery bypass grafting (CABG) is common and often requires percutaneous coronary interventions (PCI) for treatment. However, data for the effectiveness of drug-eluting stents (DES) versus bare-metal stents (BMS) in SVG-PCI are unclear. Objectives This study sought to examine the association between DES versus BMS used during SVG PCI and clinical outcomes in the national Veterans Affairs integrated healthcare systemMethods We studied a national cohort of 2,471 post-CABG veterans undergoing SVG-PCI between 2008 and 2011 at all Veterans Affairs hospitals and compared clinical outcomes of between those receiving DES and BMS. Clinical outcomes included procedural complications, myocardial infarction (MI), and all-cause mortality. Comparisons were made in a propensity-matched cohort using Cox proportional hazards regression models-absp. Results DES were used in 1,549 SVG-PCI patients (63%) and the use of DES increased progressively with each calendar year (50% in 2008 to 69% in 2011). Incidence of procedural complications was low and comparable in both groups (2.8% among BMS vs. 2.3% among DES patients; p = 0.54). During long-term (>2 years) follow-up, use of DES was associated with lower mortality than BMS (hazard ratio [HR]: 0.72; 95% confidence interval [CI]: 0.57 to 0.89) and similar rates of MI (HR: 0.94; 95% CI: 0.71 to 1.24) in the propensity-matched cohort-absp. Conclusions In a national cohort of veterans, we observed widespread and increasing use of DES during SVG-PCI. In long-term follow-up, compared with BMS, DES use was safe and effective in SVG-PCI patients.
KW - bare-metal stent
KW - drugeluting stent
KW - percutaneous coronary intervention
KW - repeat revascularization
KW - saphenous venous graft
UR - http://www.scopus.com/inward/record.url?scp=84908158566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908158566&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2014.06.1207
DO - 10.1016/j.jacc.2014.06.1207
M3 - Article
C2 - 25443706
AN - SCOPUS:84908158566
SN - 0735-1097
VL - 64
SP - 1825
EP - 1836
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 17
ER -